Latest Kaiser Health News Stories
KHN teamed up with Hulu for a discussion of America’s opioid crisis, following the Oct. 13 premiere of the online streaming service’s new series “Dopesick.”
But Americans generally have little confidence that the White House or Congress will recommend the right thing, a new poll shows.
Despite big 2020 campaign promises to deliver lower costs on prescription drugs, Democrats have failed to unite around a legislative plan.
The condition can be an early signal of Alzheimer’s disease, but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Los medicamentos que se están investigando tendrían el potencial de interferir con la capacidad del virus para replicarse en las células humanas.
At least three promising antiviral treatments for covid-19 are being tested in clinical trials, with results expected as soon as late fall or winter.
Congress is back in session with a short time to finish a long to-do list, including keeping the government operating and paying its bills. Hanging in the balance is President Joe Biden’s entire domestic agenda, including major changes proposed for Medicare, Medicaid and the Affordable Care Act. Meanwhile, the new Texas abortion law that bans the procedure early in pregnancy is prompting action in Washington. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews former FDA Commissioner Scott Gottlieb about his new book on the covid-19 pandemic.
Biologic drugs, made from living organisms, and the cheaper biosimilar drugs that mimic them are more complex than chemical drugs and their generic counterparts. The Food and Drug Administration says biosimilars are as safe and effective as the biologics, and doctors agree — but they are cautious about changing the treatment regimen of patients doing well.
The Food and Drug Administration has been mired in controversies related to drug approvals and covid vaccines, all without a permanent leader.
The House oversight committee is requesting conflict-of-interest disclosure forms from a National Academies committee studying organ transplants. KHN previously reported on apparent conflicts among members of a committee studying drug waste.
Democrats have hit a snag in their effort to compile a $3.5 trillion social-spending bill this fall — moderates are resisting support for Medicare drug price negotiation provisions that would pay for many of the measure’s health benefit improvements. Meanwhile, the new abortion restrictions in Texas have moved the divisive issue back to the political front burner. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Shefali Luthra of The 19th join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interview’s KHN’s Phil Galewitz about the latest KHN-NPR “Bill of the Month” installment, about two similar jaw surgeries with very different price tags.
Despite widespread consensus on the importance of addiction treatment in the ER, many hospitals fail to screen for substance use, offer medications to treat opioid use disorder or connect patients to follow-up care. But some are working to change that.
Governors in Southern states, amid a surge of delta-variant infections, are rushing to provide an experimental antibody cocktail therapy, even as they oppose measures like mask mandates and vaccine passports that health officials say can prevent infection in the first place.
Many experts say the evidence doesn’t justify widespread booster shots for adults.
La administración de Biden anunció el miércoles 18 de agosto planes para ofrecer refuerzos de la vacuna contra covid-19 a todos los adultos estadounidenses a partir del próximo mes.
Federal officials are preparing to offer those who received Pfizer or Moderna covid vaccines a third dose in September. But the FDA and CDC are still reviewing the data for final clearance.
While many businesses scaled back at the height of the pandemic, one Montana man used covid-19 to open his own mobile pharmacy. He’s now bringing covid shots to Montana’s vaccine deserts while filling his wallet. But he cannot fill all the vaccination gaps.
Pfizer anunció su ensayo global de fase 3 sobre una tercera dosis a mediados de julio. La fecha de finalización de ese ensayo es en 2022. Los resultados de la fase 3 suelen ser necesarios antes de la aprobación oficial.
As pharmaceutical companies declare a need for boosters, scientists and doctors emphasize there’s no proof yet.